“Triple Negative Breast Cancer Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Triple Negative Breast Cancer Market.
The Triple Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Get a Free Sample PDF Report to know more about Triple Negative Breast Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight
Some of the key takeaways from the Triple Negative Breast Cancer Pipeline Report:
Companies across the globe are diligently working toward developing novel Triple Negative Breast Cancer treatment therapies with a considerable amount of success over the years.
Triple Negative Breast Cancer companies working in the treatment market are Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others, are developing therapies for the Triple Negative Breast Cancer treatment
Emerging Triple Negative Breast Cancer therapies in the different phases of clinical trials are- SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others are expected to have a significant impact on the Triple Negative Breast Cancer market in the coming years.
In October 2026, Recent research highlights reported promising progress in TNBC vaccine development. A Phase I vaccine study generated an immune response in 74% of participants and is advancing to Phase II evaluation. The approach is investigational and intended for people at high risk of developing TNBC
In September 2026, Results from the NSABP B-59/GeparDouze trial, published in Nature Medicine, showed that adding atezolizumab to neoadjuvant chemotherapy did not significantly improve event-free survival in patients with Stage II–III TNBC. Four-year event-free survival was 85.2% with atezolizumab versus 81.9% with placebo, but the primary endpoint was not met. Exploratory subgroup findings require further evaluation.
In September 2026, FDA Grants Full Approval to Sacituzumab Govitecan-Based Regimens for First-Line TNBC. Two approvals under Project Orbis establish sacituzumab govitecan-based treatments as a new standard of care for patients with both PD-L1–positive and PD-L1–negative metastatic triple-negative breast cancer (mTNBC). Additionally, exploratory findings from the ASCENT-04/KEYNOTE-D19 trial indicate that the clinical benefits of frontline sacituzumab govitecan may continue even after disease progression, despite many patients in the control group later receiving the same therapy.
In August 2026, Gilead Sciences announced that the European Commission (EC) has approved Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The approval applies to patients whose tumors are PD-L1 positive with a combined positive score (CPS) of 10 or higher and who have not previously received systemic treatment for metastatic disease.
In June 2026, The U.S. FDA approved Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The approval covers its use as monotherapy for patients who are ineligible for PD-1/PD-L1 inhibitor-based therapy and in combination with pembrolizumab for patients with PD-L1-positive tumors, expanding first-line treatment options for metastatic TNBC.
In May 2026, The FDA approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo) for adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are not eligible for PD-1/PD-L1 inhibitor therapy.
In February 2026, The U.S. Food and Drug Administration (FDA) granted Priority Review to AstraZeneca’s Datroway (datopotamab deruxtecan) following acceptance of its supplemental Biologics License Application (sBLA). The application seeks approval for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not eligible for PD-L1 inhibitor therapy. According to the company, Datroway has the potential to become a new standard of care in this setting, where chemotherapy has traditionally been the only approved option. Priority Review is typically awarded to therapies that may offer meaningful improvements in safety or effectiveness compared to existing treatments.
In January 2026, CytoDyn (OTCQB: CYDY) announced that an anonymous donor has provided funding to support an Expanded Access Program (EAP) allowing patients with triple-negative breast cancer (TNBC) to receive leronlimab. The company has partnered with WEP Clinical as the CRO and plans to open the program for patient referrals in March 2026, pending FDA approval of a revised protocol. The EAP is designed for patients who have exhausted approved therapies and do not qualify for ongoing clinical trials. The program may also offer insights into PD-L1 induction after leronlimab and potential combination strategies with immune checkpoint inhibitors. Additional details for physicians and patients will be shared on the company’s website as the program progresses.
In September 2025, ProteinQure, a Toronto-based biotech specializing in computational peptide drug discovery, announced the first patient has been dosed in its Phase I clinical trial of PQ203, a novel peptide therapeutic for advanced metastatic solid tumors. This marks the company’s first internally developed AI-designed peptide therapy to reach the clinic, just three years after the program’s initiation. PQ203 consists of a peptide targeting the Sortilin receptor linked to the cytotoxic agent MMAE. Since the Sortilin receptor is highly expressed in diseased tissue of Triple Negative Breast Cancer (TNBC) patients, PQ203 has shown strong efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), the current standard of care for metastatic TNBC.
Triple Negative Breast Cancer Overview
Triple-Negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). It accounts for approximately 10–15% of breast cancer cases and is often associated with a higher risk of early recurrence and metastasis. Common symptoms include a breast lump, changes in breast shape, skin dimpling, and nipple discharge. Treatment options include chemotherapy, immunotherapy, targeted therapies for eligible patients, and surgery. Ongoing research focuses on developing novel targeted treatments and improving long-term survival outcomes.
Explore the latest Triple Negative Breast Cancer pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Triple Negative Breast Cancer Clinical Trials
Emerging Triple Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:
SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
AK117: Akeso Biopharma
PLX038: ProLynx
mRNA-2752: ModernaTX, Inc.
OTS167PO: OncoTherapy Science
PMD-026: Phoenix Molecular Designs
X4P-001: Abbisko Therapeutics
BLEX 404: BioLite, Inc.
ZEN003694 +Talazoparib: Zenith Epigenetics
mprime PGG: HiberCell, Inc.
IPI-549: Infinity Pharmaceuticals
Trilaciclib: G1 Therapeutics, Inc
Camrelizumab: Jiangsu HengRui Medicine Co., Ltd
HLX10: Shanghai Henlius Biotech
Triple Negative Breast Cancer Route of Administration
Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Triple Negative Breast Cancer Molecule Type
Triple Negative Breast Cancer Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Triple Negative Breast Cancer Pipeline Therapeutics Assessment
Triple Negative Breast Cancer Assessment by Product Type
Triple Negative Breast Cancer By Stage and Product Type
Triple Negative Breast Cancer Assessment by Route of Administration
Triple Negative Breast Cancer By Stage and Route of Administration
Triple Negative Breast Cancer Assessment by Molecule Type
Triple Negative Breast Cancer by Stage and Molecule Type
DelveInsight’s Triple Negative Breast Cancer Report covers around 170+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Triple Negative Breast Cancer product details are provided in the report. Download the Triple Negative Breast Cancer pipeline report to learn more about the emerging Triple Negative Breast Cancer therapies
Some of the key companies in the Triple Negative Breast Cancer Therapeutics Market include:
Key companies developing therapies for Triple Negative Breast Cancer are – ModernaTX, Inc, NuGenerex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others.
Triple Negative Breast Cancer Pipeline Analysis:
The Triple Negative Breast Cancer pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
Triple Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Triple Negative Breast Cancer drugs and therapies
Triple Negative Breast Cancer Pipeline Market Drivers
Increase in the prevalence of Triple Negative Breast Cancer, increasing Research and Development activities are some of the important factors that are fueling the Triple Negative Breast Cancer Market.
Triple Negative Breast Cancer Pipeline Market Barriers
However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Triple Negative Breast Cancer Market growth.
Scope of Triple Negative Breast Cancer Pipeline Drug Insight
Coverage: Global
Key Triple Negative Breast Cancer Companies: Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others
Key Triple Negative Breast Cancer Therapies: SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others
Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies
Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers
Request for Sample PDF Report for Triple Negative Breast Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Triple Negative Breast Cancer Report Introduction
2. Triple Negative Breast Cancer Executive Summary
3. Triple Negative Breast Cancer Overview
4. Triple Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment
5. Triple Negative Breast Cancer Pipeline Therapeutics
6. Triple Negative Breast Cancer Late Stage Products (Phase II/III)
7. Triple Negative Breast Cancer Mid Stage Products (Phase II)
8. Triple Negative Breast Cancer Early Stage Products (Phase I)
9. Triple Negative Breast Cancer Preclinical Stage Products
10. Triple Negative Breast Cancer Therapeutics Assessment
11. Triple Negative Breast Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Triple Negative Breast Cancer Key Companies
14. Triple Negative Breast Cancer Key Products
15. Triple Negative Breast Cancer Unmet Needs
16 . Triple Negative Breast Cancer Market Drivers and Barriers
17. Triple Negative Breast Cancer Future Perspectives and Conclusion
18. Triple Negative Breast Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
The post Triple Negative Breast Cancer Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs first appeared on PressReleaseCC.
